Board of Directors

Board of Directors

Board of Directors

Biopta Ltd is the leading company focussed on the use of fresh functional human tissues in drug development.  The company benefits from an experienced board of directors with particular skills in life sciences, pharmacology and high growth companies.

Chikafumi Yokoyama, Chairman.

Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of the business development division and became Chief Executive Officer in 2005. He has been responsible for new product management, alliance, and fund raising. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, Dr Yokoyama worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, as an R&D leader. He received his Ph.D. in chemistry from Tokyo University in 1996


Daigo Obita – Director.

Mr. Obita joined ReproCELL Inc. in 2014 as a general manager in the administration department and became director in 2015. Before joining the company, from 1996 to 2008, Mr. Obita worked for the Bank of Yokohama, Ltd. Then, from 2008 to 2014 he joined Rakuten at Finance Department and Rakuten EMOBILE, Inc. as a director. He received a bachelor of Business Administration from Yokohama National University in 1996.


Dr David Bunton, CEO.

David, an experienced and respected human tissue pharmacologist, is one of the co-founders of Biopta Ltd. Prior to forming Biopta, David was a Lecturer in Physiology and Pharmacology at Glasgow Caledonian University and remains a regular contributor to the field of human tissue research. David is a member of the British Pharmacological Society and Safety Pharmacology Society and is also active in promoting greater access to human tissues for medical research in the UK and USA.


Elaine Ferguson CA, Finance Director.

Elaine is a Chartered Accountant with many years of first-hand experience in high-growth businesses. Elaine joined Biopta in 2007 having previously held roles at Ernst & Young, CCL Limited and Scottish Enterprise. Elaine has been critical to Biopta’s success both in raising equity investments and creating a profitable platform for growth in the rapidly expanding field of human tissue services.


Live chat by BoldChat